GeneCure Biosciences, a Hyderabad-based biotech working on gene therapies for inherited blood disorders, has closed a ₹150 crore Series A round led by Endiya Partners, with participation from the Biotechnology Industry Research Assistance Council.

The funding will primarily support phase two clinical trials for the company's lead candidate, a therapy targeting beta-thalassemia, a genetic blood disorder that affects an estimated 1 in 2,700 births in India.

"India has one of the highest burdens of thalassemia in the world, and until now most treatment options have been palliative rather than curative," said Dr. Ananya Reddy, GeneCure's founder and chief scientific officer.

GeneCure expects to begin patient enrolment for the phase two trial by early next year, across five hospitals in Hyderabad and Bengaluru.